Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570726 · ClinicalTrials.gov registry record · Phase 1
Treatment of Failing Blebs With Ranibizumab
A Phase 1 study, sponsored by The New York Eye & Ear Infirmary.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00570726 is a Phase 1 study that has completed, run by The New York Eye & Ear Infirmary. The registered enrollment target is 6 participants.
The verdict
NCT00570726, a Phase 1 study, has completed, sponsored by The New York Eye & Ear Infirmary.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva, following trabeculectomy. Six subjects from one site will be enrolled in this study.
Interventions
- DRUG Ranibizumab (Lucentis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2000-06 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570726
The ClinicalTrials.gov registry entry for NCT00570726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The New York Eye & Ear Infirmary, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab (Lucentis) is the first listed.
NCT00570726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00570726 about?
NCT00570726 is a clinical study titled "Treatment of Failing Blebs With Ranibizumab". This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva, following trabeculectomy. Six ...
What is the current status of trial NCT00570726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2000-06. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00570726?
The interventions under investigation include: Ranibizumab (Lucentis) (DRUG).
Who is sponsoring clinical trial NCT00570726?
This trial is sponsored by The New York Eye & Ear Infirmary, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.